Figure 4.

Comparative analysis of PD-L1 expression on tumor cells (TC) and immune cells (IC) with various molecular subgroups of lung cancer patients (ALK-positive, EGFR-mutated and WT (non -EGFR-mutated, non-KRAS-mutated, non-ALK-positive)). PD-L1 was quantitated as a continuous variable and either as a percentage of tumor cells (A), number of PD-L1⁺ stromal/immune cells per field (fd)(B), or total number of PD-L1⁺ tumor cells and PD-L1⁺ stromal cells per field (C). These parameters were compared between the three subgroups of lung cancer patients. Percentage of patients whose tumors expressed PD-L1 with cut-offs greater than 1% (D), 10% (E) and 50% (F).